Patheon Inc. Signs Agreements to Commercialize OROS-Based Controlled Release Products

    RESEARCH TRIANGLE PARK, NC, April 27 /CNW/ - Patheon Inc. (TSX: PTI), a
global provider of drug development and manufacturing services to the
international pharmaceutical industry, is pleased to announce that is has
signed agreements to commercialize two OROS technology controlled release
products from their Cincinnati facility. The first product will launch in late
2009 and the second is planned to launch in the third quarter of 2010.
    OROS is a specialized drug delivery technology used to achieve the
controlled release of active drug substances. When a patient swallows an OROS
tablet, water is drawn into a specially formulated portion of the tablet which
swells, exerting pressure on the tablet drug layer. This gentle pressure
forces the active drug out through laser-drilled holes in the tablet, allowing
for a gradual release of the active drug substance.
    Patheon has developed the expertise for the OROS technology in
collaboration with clients and the equipment manufacturer and developed the
Cincinnati facility as the Center of Excellence for controlled release
technologies. Terry Novak, President of North America and Chief Commercial
Officer stated, "This process is very unique and requires special equipment
and expertise to successfully develop and commercialize OROS-based products.
Having the development and commercial expertise available at our Cincinnati
facility allows our customers to quickly and successfully launch OROS-based
products and extend the life cycle of their products."


    Patheon Inc. (TSX: PTI; is a leading global provider of
contract development and manufacturing services to the pharmaceutical
industry. Patheon prides itself in providing the highest quality products and
services to more than 300 of the world's leading pharmaceutical and
biotechnology companies. Patheon's services range from preclinical development
through commercial manufacturing of a wide array of dosage forms including
parenteral, solid, semi-solid and liquids.
    Patheon's comprehensive range of fully integrated Pharmaceutical
Development Services includes pre-formulation, formulation, analytical
development, clinical manufacturing, scale-up and commercialization. Patheon's
ability to integrate development and manufacturing services ensures that our
customers' projects are delivered on time and meet the high standards of
quality that Patheon is known for.
    Patheon's integrated network strives to ensure that customer products can
be launched with confidence globally.

    Caution Concerning Forward-Looking Statements

    This news release may contain forward-looking statements which reflect
management's expectations regarding the Company's future growth of operations,
performance (both operational and financial) and business prospects and
opportunities. These statements are made in the context of the risks and
uncertainties that are outlined in the Company's public documents, which can
be accessed on our website at or on SEDAR at

    %SEDAR: 00001700E

For further information:

For further information: Mr. Wes Wheeler, President & Chief Executive
Officer, Tel: (919) 226-3200, Email:; Mr. Terry Novak,
President of North America, Chief Commercial Officer, Tel: (919) 226-3209,
Email:; Mr. Eric Evans, Chief Financial Officer, Tel:
(919) 226-3200, Email:

Organization Profile

Patheon Inc

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890